Clinical Trials Sponsored by First Horizon

Total 5157 results

Viela Bio (acquired by Horizon Therapeutics)

Completed

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis (MIDORA)

Rheumatoid Arthritis

United States, Poland
Horizon Health Network
Canada Health Infoway

Unknown

TelePremie: Telehomecare for Step-down Care Post-NICU Discharge

Anxiety | Self Efficacy

Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Drug Toxicity

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Terminated

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
Viela Bio (acquired by Horizon Therapeutics)

Completed

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Kidney Transplantation | Transplant Rejection | Allografts | Rejection; Transplant, Kidney

United States
Viela Bio (acquired by Horizon Therapeutics)

Completed

A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

Dendritic Cell -Mediated Rheumatic Diseases

United States, Poland
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis (JIA)

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis (CAPRA-2)

Rheumatoid Arthritis

United States, Germany, Hungary, Canada, Poland, United Kingdom
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) (HZ-CA-304)

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
Sun Yat-sen University
New Horizon Health

Recruiting

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Colorectal Cancer

China
Rigshospitalet, Denmark
Horizon 2020 - European Commission; IrsiCaixa

Not yet recruiting

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events (MISTRAL)

Inflammation | HIV-1-infection | AIDS

Spain, United Kingdom, Denmark, France, Israel, Germany, Belgium, Croatia, Czechia, Greece, Hungary, Italy, Luxembourg, Poland
AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
Verizon Wireless

Unknown

Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure

Heart Failure

United States
University Hospital, Bordeaux
Horizon 2020 - European Commission

Recruiting

Ground-Breaking Electroporation-based Intervention for PERSistent Atrial Fibrillation Treatment (BEAT PERS-AF) (BEAT PERS-AF)

Atrial Fibrillation

Austria, France, Czechia, Belgium, Germany
Rockfield Medical Devices
Horizon 2020 - European Commission

Enrolling by invitation

Safety and Effectiveness of A Novel Enteral Feeding System: Prospective Study.

Enteral Feeding

United States
Universidade do Porto
Horizon 2020 - European Commission

Recruiting

Testing an e-Health Intervention for Prostate Cancer Survivors' Mental and Sexual Health

Prostate Cancer

Portugal
University of Basel
Horizon 2020 - European Commission

Not yet recruiting

Effect of Different Color Lights on the Internal Clock and Alertness in Humans (CONE)

Light Flashing

Switzerland
Academisch Ziekenhuis Maastricht
Horizon 2020 - European Commission

Not yet recruiting

Effects of VitamIN K2 and D3 supplementaTion on PET/MRI in Carotid Artery Disease (INTRICATE)

Coronary Artery Disease | Carotid Artery Disease
University of Pittsburgh
Horizon Pharma USA, Inc.

Recruiting

Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community

Undiagnosed Disease

United States
University of Malaga
Horizon 2020 - European Commission

Enrolling by invitation

Digital Intervention for the Modification of Lifestyles (iGame)

Depression | Low Back Pain | Sedentary Lifestyle | Sedentary Behavior | Oncology

Spain
Lille Catholic University
Horizon Pharma Rheumatology LLC

Completed

Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit (GOUT)

Gout

France
Örebro University, Sweden
Horizon 2020 - European Commission

Completed

Impact of Healthy Diet on Metabolic Health in Men and Women

Metabolic Syndrome | Healthy Aging | Diet, Healthy

Sweden
Belkin Laser Ltd.
Horizon 2020 - European Commission

Completed

Direct Application of Selective Laser Trabeculoplasty in Open Angle Glaucoma

Glaucoma

Israel
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetics of ODM-209 (STESIDES)

Advanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Finland, France, Denmark
Orion Corporation, Orion Pharma

Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (EASYRELIEF)

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Completed

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
Orion Corporation, Orion Pharma

Terminated

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway (BufoSwitch)

Asthma | COPD

Norway
Orion Corporation, Orion Pharma

Completed

Blood-Brain Barrier Penetration of Therapeutic Agents in Human (BRIAN)

CNS Disease

Finland
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler (TIOPIF)

Healthy Volunteer | COPD

Estonia
Orion Corporation, Orion Pharma

Completed

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Prostate Cancer

United States, United Kingdom, Finland, France, Estonia, Czech Republic
Orion Corporation, Orion Pharma

Completed

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product (BUFODIL)

Asthma

Bulgaria
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Single Doses of ORM-12741 (Nebula PK 1)

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study in Healthy Males (NOCOF)

Parkinson's Disease

Finland
Orion Corporation, Orion Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers (NOCOS)

Healthy

Germany
Orion Corporation, Orion Pharma

Completed

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations (PARPOC)

Parkinson's Disease
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol

Healthy

Germany
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741

Healthy

France
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets

Healthy

India
Orion Corporation, Orion Pharma

Completed

Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

Healthy

Finland
Orion Corporation, Orion Pharma

Completed

Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation (PEGorion)

Constipation

Finland

Clinical Trials Sponsored by First Horizon

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations